- Home
- DBVT vs IKNA Comparison
DBVT vs IKNA Comparison
Compare DBVT & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBVT
- IKNA
- Stock Information
- Founded
- DBVT 2002
- IKNA 2016
- Country
- DBVT France
- IKNA United States
- Employees
- DBVT N/A
- IKNA N/A
- Industry
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- DBVT Health Care
- IKNA Health Care
- Exchange
- DBVT Nasdaq
- IKNA Nasdaq
- Market Cap
- DBVT 250.5M
- IKNA 63.7M
- IPO Year
- DBVT N/A
- IKNA 2021
- Fundamental
- Price
- DBVT $10.30
- IKNA $1.43
- Analyst Decision
- DBVT Buy
- IKNA Strong Buy
- Analyst Count
- DBVT 4
- IKNA 1
- Target Price
- DBVT $14.81
- IKNA $4.00
- AVG Volume (30 Days)
- DBVT 25.0K
- IKNA 105.8K
- Earning Date
- DBVT 07-29-2025
- IKNA 08-07-2025
- Dividend Yield
- DBVT N/A
- IKNA N/A
- EPS Growth
- DBVT N/A
- IKNA N/A
- EPS
- DBVT N/A
- IKNA N/A
- Revenue
- DBVT $3,497,000.00
- IKNA N/A
- Revenue This Year
- DBVT $1,700.53
- IKNA N/A
- Revenue Next Year
- DBVT $535.67
- IKNA N/A
- P/E Ratio
- DBVT N/A
- IKNA N/A
- Revenue Growth
- DBVT N/A
- IKNA N/A
- 52 Week Low
- DBVT $2.21
- IKNA $0.97
- 52 Week High
- DBVT $12.78
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- DBVT 56.17
- IKNA 56.42
- Support Level
- DBVT $10.11
- IKNA $1.33
- Resistance Level
- DBVT $11.84
- IKNA $1.43
- Average True Range (ATR)
- DBVT 0.67
- IKNA 0.05
- MACD
- DBVT 0.05
- IKNA -0.00
- Stochastic Oscillator
- DBVT 60.06
- IKNA 59.91
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.